Pipeline Project Director Perry
Cohen, Ph.D., is participating in ANSI workgroup. This
task force is defining standards for inter-operable electronic
medical records.
Book: "Monkeys
in the Middle: How One Drug Company Kept a Parkinson's Disease
Breakthrough Out of Reach" by
investigative journalist Nick Nelson, has just been
published and is available on Amazon.
The "Access, Compassion, Care, and Ethics for
Seriously Ill Patients Act"
or the Access Act (S3046 ) was
introduced in the Senate in May. It is a bill to amend the
Federal Food, Drug, and Cosmetic Act to create a new
conditional approval system for drugs, biological products, and
devices that is responsive to the needs of seriously ill
patients, and for other purposes. For Details seeLibrary
of Congress, Thomas
Past What's New items have been
archived on this page.
The Parkinson Pipeline
Project is supported by
the Parkinson's Disease Foundation (PDF),
a 501(c)3 Corporation headquartered in
New York City.
Tax deductible donations to the Parkinson
Pipeline Project, made through this website to Donate.net,
go
to the PDF designated for use by the Parkinson Pipeline
Project.
FIND
A CLINICAL TRIAL
What is the
Pipeline Project?
The Parkinson Pipeline Project is a grassroots group of advocates
whose goal is to provide the patient perspective in the
treatment development process. Through education,
consultation, and participation with all stakeholders -
including industry and the FDA - the Parkinson Pipeline
Project hopes to increase clinical trial participation and
accelerate approved treatment options. New PD treatments
are followed from pre-clinical development to approval in the
Pd Pipeline Database found on our website. More info...
"The missing ingredient in the
development of new therapies is the voice of the
patient."
Perry D Cohen, Project
Director
Declaration of
Clinical Research Rights and Responsibilities
for People With Parkinson’s
Clinical research is essential to
the development of new therapies and treatments for
Parkinson’s disease. Yet, due to a number of factors,
including a lack of awareness and understanding of the
research process, only one percent of people with
Parkinson’s participate. This is far below the number
needed, delaying many promising trials. Read the entire Declaration!
Parkinson's
Disease Clinical Trials: Square Pegs in Round Holes?
Poster
presented by the Parkinson Pipeline
Project at the
2009 American Society for Experimental Neurotherapeutics
(ASENT) Conference
Your access
to and use of the information contained in this web site is
subject to this Terms and Conditions of Use Agreement. By
accessing and using this web site, you accept this Terms and
Conditions of Use Agreement.
The contents
of this website and all communications with Parkinson
Pipeline Project (PPP) are solely for information purposes
and are not intended as medical advice. While we make
every effort to assure that the information is accurate and
up to date, an error may >occasionally occur. All information
and materials are provided AS IS without any warranty of any
kind. In no event will the PPP be held liable for any
damages arising out of information contained in our website.
If any
provision of this Terms and Conditions of Use Agreement is
held to be unlawful, void, or unenforceable, then such
provision shall be deemed severed without affecting the
enforceability of all remaining provisions.
